Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Depreciation & Amortization (CF) (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Depreciation & Amortization (CF) data on record, last reported at $1.2 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 31.13% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $4.3 million, up 14.18%, while the annual FY2025 figure was $4.3 million, 14.18% up from the prior year.
  • Depreciation & Amortization (CF) reached $1.2 million in Q4 2025 per OCUL's latest filing, up from $1.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.2 million in Q4 2025 and bottomed at $483000.0 in Q1 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $781100.0, with a median of $771000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): fell 14.54% in 2021, then surged 95.11% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $570000.0 in 2021, then dropped by 13.86% to $491000.0 in 2022, then skyrocketed by 95.11% to $958000.0 in 2023, then fell by 0.73% to $951000.0 in 2024, then surged by 31.13% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $1.2 million in Q4 2025, $1.1 million in Q3 2025, and $1.0 million in Q2 2025.